Federal Register / Vol. 63, No. 137 / Friday, July 17, 1998 / Notices 38671

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 97–29]

David M. Rose, MD.; Revocation of

Registration

On May 15, 1997, the Deputy

Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration (DEA), issued an Order

to Show Cause to David M. Rose, M.D.

(Respondent), of Massachusetts,

notifying him of an opportunity to show

cause as to why DEA should not revoke

his DEA Certificate of Registration,

BR2726365, under 21 U.S.C. 824(a)(3),

and deny any pending applications for

renewal of such registration as a

practitioner pursuant to 21 U.S.C.

823(f), for reason that he is not currently

authorized to handle controlled

substances in the Commonwealth of

Massachusetts.

The Order to Show Cause was

ultimately received by Respondent on

August 12, 1997, In a letter to the DEA

Office of Administrative Law Judges

dated August 15, 1997. Respondent did

not dispute that his license to practice

medicine in the Commonwealth of

Massachusetts was suspended.

Respondent further stated, ‘‘[h]owever, I

am soon to enter into a probationary

agreement with [the Massachusetts

Board of Medicine] that will allow me

to practice medicine in a restricted and

monitored fashion[.] I wonder if then at

that time it would be possible for me to

apply for some sort of DEA license with

whatever restrictions [DEA] would

deem appropriate, so that I may

prescribe medications if and when I am

allowed to continue practice?’’

Respondent did not request a hearing on

the issues raised by the Order to Show

Cause.

The matter was docketed before

Administrative Law Judge Mary Ellen

Bittner. On October 16, 1997,

Government counsel sent a letter to

Respondent which advised him that he

could either surrender his DEA

Certificate of Registration, request a

hearing, or waive his right to a hearing

and submit a written statement for

consideration regarding the proposed

revocation of his registration.

Respondent was further advised that if

he surrendered his registration or DEA

revoked it, he could reapply for a new

DEA Certificate of Registration upon

reinstatement of his state license, but

that his DEA registration would not be

automatically reinstated if he regains his

state license.

Thereafter, on November 3, 1997, the

Office of Administrative Law Judges

sent Respondent a letter advising him

that if no request for a hearing was

received by November 24, 1997, he

would be deemed to have waived his

right to a hearing. On December 8, 1997,

Judge Bittner issued a Memorandum

and Order stating that since no request

for a hearing was received, Respondent

was deemed to have waived his

opportunity for a hearing pursuant to 21

CFR 1301.43(d). Consequently, after

considering relevant material from the

investigative file, the Acting Deputy

Administrator now enters his final order

without a hearing pursuant to 21 CFR

1301.43 (d) and (e) and 1301.46.

The Acting Deputy Administrator

finds that on November 9, 1994, the

Commonwealth of Massachusetts, Board

of Registration in Medicine issued an

Order of Suspension of Respondent’s

license to practice medicine in the

Commonwealth of Massachusetts. The

suspension was based on charges

related to Respondent’s mental

condition and dependence on alcohol

and drugs; the substandard quality of

medical care Respondent provided;

Respondent’s false statements on his

Massachusetts license renewal

application; and his violation of the

Controlled Substances Act.

Respondent did not present any

evidence that his Massachusetts medical

license has been reinstated. Therefore,

the Acting Deputy Administrator finds

that Respondent is not currently

authorized to practice medicine in the

Commonwealth of Massachusetts. The

Acting Deputy Administrator further

finds that it is reasonable to infer that

Respondent is also not authorized to

handle controlled substances in that

state. The DEA does not have the

statutory authority under the Controlled

Substances Act to issue or maintain a

registration if the applicant or registrant

is without state authority to handle

controlled substances in the state in

which he conducts his business. 21

U.S.C. 802(21), 823(f) and 824(a)(3).

This prerequisite has been consistently

upheld. See Romeo J. Perez, M.D., 62 FR

16,193 (1997); Demetris A. Green, M.D.,

61 FR 60,728 (1996); Dominick A. Ricci,

M.D., 58 FR 51,104 (1993).

Here it is clear that Respondent is not

currently authorized to handle

controlled substances in the

Commonwealth of Massachusetts.

Therefore, he is not entitled to a DEA

registration in that state.

Accordingly, the Acting Deputy

Administrator of the Drug Enforcement

Administration, pursuant to the

authority vested in him by 21 U.S.C. 823

and 824 and 28 CFR 0.100(b) and 0.104,

hereby orders that DEA Certificate of

Registration, BR2726365, previously

issued to David M. Rose. M.D., be, and

it hereby is, revoked. The Acting Deputy

Administrator further orders that any

pending applications for the renewal of

such registration, be, and they hereby

are, denied. This order is effective

August 17, 1998.

Dated: July 10, 1998.

Donnie R. Marshall,

Acting Deputy Administrator.

[FR Doc. 98–19083 Filed 7–16–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DEA#167R]

Controlled Substances: Proposed

Revised Aggregate Production Quotas

for 1998

AGENCY: Drug Enforcement

Administration (DEA), Justice.

ACTION: Notice of proposed revised 1998

aggregate production quotas.

SUMMARY: This notice proposes revised

1998 aggregate production quotas for

controlled substances in Schedules I

and II of the Controlled Substances Act

(CSA).

DATES: Comments or objections should

be received on or before August 17,

1998.

ADDRESSES: Send comments or

objections to the Acting Deputy

Administrator, Drug Enforcement

Administration, Washington, DC 20537,

Attn.: DEA Federal Register

Representative (CCR).

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone:

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section

306 of the CSA (21 U.S.C. 826) requires

that the Attorney General establish

aggregate production quotas for each

basic class of controlled substance listed

in Schedules I and II. This

responsibility has been delegated to the

Administrator of the DEA by Section

0.100 of Title 28 of the Code of Federal

Regulations. The Administrator, in turn,

has redelegated this function to the

Deputy Administrator of the DEA

pursuant to Section 0.104 of Title 28 of

the Code of Federal Regulations.

On November 21, 1997, a notice of

established initial 1998 aggregate

production quotas for certain controlled

substances in Schedules I and II was

published in the Federal Register (62

FR 62349). The notice proposing initial
38672 Federal Register / Vol. 63, No. 137 / Friday, July 17, 1998 / Notices

1998 aggregate production quotas (62 FR

46373) stipulated that the Deputy

Administrator of the DEA would adjust

the quotas in early 1998 as provided for

in Section 1303 of Title 21 of the Code

of Federal Regulations.

The proposed revised 1998 aggregate

production quotas represent those

quantities of controlled substances that

may be produced in the United States in

1998 to provide adequate supplies of

each substance for: the estimated

medical, scientific, research, and

industrial needs of the United States;

lawful export requirements; and the

establishment and maintenance of

reserve stocks. These quotas do not

include imports of controlled

substances for use in industrial

processes.

The proposed revisions are based on

a review of 1997 year-end inventories,

1997 disposition data submitted by

quota applicants, estimates of the

medical needs of the United States, and

other information available to the DEA.

Therefore, under the authority vested

in the Attorney General by Section 306

of the CSA of 1970 (21 U.S.C. 826),

delegated to the Administrator of the

DEA by Section 0.100 of Title 28 of the

Code of Federal Regulations, and

redelegated to the Deputy Administrator

pursuant to Section 0.104 of Title 28 of

the Code of Federal Regulations, the

Acting Deputy Administrator hereby

proposes the following revised 1998

aggregate production quotas for the

following controlled substances,

expressed in grams of anhydrous acid or

base:

Basic class

Previously established initial

1998 quotas

Proposed revised 1998

quotas

Schedule I:

2, 5-Dimethoxyamphetamine ............................................................................................................................ 15,000,100 20,000,100

2, 5-Dimethoxy-4-ethylamphetamine (DOET) .................................................................................................. 2 2

3-Methylfentanyl ................................................................................................................................................ 14 14

3-Methylthiofentanyl .......................................................................................................................................... 2 2

3,4-Methylenedioxyamphetamine (MDA) .......................................................................................................... 25 25

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ........................................................................................... 30 30

3,4-Methylenedioxymethamphetamine (MDMA) ............................................................................................... 20 20

3,4,5-Trimethoxyamphetamine ......................................................................................................................... 2 2

4-Bromo-2,5-Dimethoxyamphetamine (DOB) ................................................................................................... 2 2

4-Bromo-2,5-Dimethoxyphenethylamine (2–CB) .............................................................................................. 2 2

4-Methoxyamphetamine .................................................................................................................................... 100,100 100,100

4-Methylaminorex .............................................................................................................................................. 2 2

4-Methyl-2,5-Dimethoxyamphetamine (DOM) .................................................................................................. 2 2

5-Methoxy-3,4-Methylenedioxyamphetamine ................................................................................................... 2 2

Acetyl-alpha-methylfentanyl .............................................................................................................................. 2 2

Acetylmethadol .................................................................................................................................................. 7 7

Allylprodine ........................................................................................................................................................ 2 2

Alpha-acetylmethadol ........................................................................................................................................ 7 7

Alpha-ethyltryptamine ....................................................................................................................................... 2 2

Alphameprodine ................................................................................................................................................ 2 2

Alpha-methadol ................................................................................................................................................. 2 2

Alpha-methylfentanyl ......................................................................................................................................... 2 2

Alphaprodine ..................................................................................................................................................... 2 2

Alpha-methylthiofentanyl ................................................................................................................................... 2 2

Aminorex ........................................................................................................................................................... 7 7

Beta-acetylmethadol ......................................................................................................................................... 2 2

Beta-hydroxyfentanyl ........................................................................................................................................ 2 2

Beta-hydroxy-3-methylfentanyl ......................................................................................................................... 2 2

Beta-methadol ................................................................................................................................................... 2 2

Betaprodine ....................................................................................................................................................... 2 2

Bufotenine ......................................................................................................................................................... 2 2

Cathinone .......................................................................................................................................................... 9 9

Codeine-N-oxide ............................................................................................................................................... 2 2

Diethyltryptamine .............................................................................................................................................. 2 2

Difenoxin ........................................................................................................................................................... 16,000 16,000

Dihydromorphine ............................................................................................................................................... 7 7

Dimethyltryptamine ........................................................................................................................................... 2 2

Ethylamine Analog of PCP ............................................................................................................................... 5 5

Heroin ................................................................................................................................................................ 2 2

Hydroxypethidine .............................................................................................................................................. 2 2

Lysergic acid diethylamide (LSD) ..................................................................................................................... 57 57

Mescaline .......................................................................................................................................................... 7 7

Methaqualone ................................................................................................................................................... 17 17

Methcathione ..................................................................................................................................................... 11 11

Morphine-N-oxide .............................................................................................................................................. 2 2

N-Ethylamphetamine ......................................................................................................................................... 7 7

N-Hydroxy-3,4-Methylenedioxyamphetamine ................................................................................................... 4 4

N,N-Dimethylamphetamine ............................................................................................................................... 7 7

Noracymethadol ................................................................................................................................................ 2 2

Norlevorphanol .................................................................................................................................................. 2 2

Normethadone .................................................................................................................................................. 7 7

Normorphine ..................................................................................................................................................... 7 7

Para-fluorofentanyl ............................................................................................................................................ 2 2

Pholcodine ........................................................................................................................................................ 2 2

Psilocin .............................................................................................................................................................. 2 2
Federal Register / Vol. 63, No. 137 / Friday, July 17, 1998 / Notices 38673

Basic class

Previously established initial

1998 quotas

Proposed revised 1998

quotas

Psilocybin .......................................................................................................................................................... 2 2

Tetrahydrocannabinols ...................................................................................................................................... 26,000 31,000

Thiofentanyl ....................................................................................................................................................... 2 2

Trimeperidine .................................................................................................................................................... 2 2

Schedule II:

1-Phenylcyclohexylamine .................................................................................................................................. 15 15

1-Piperidinocyclohexanecarbonitrile (PCC) ...................................................................................................... 12 12

Alfentanil ........................................................................................................................................................... 8,100 8,100

Amobarbital ....................................................................................................................................................... 12 12

Amphetamine .................................................................................................................................................... 4,037,000 4,178,000

Cocaine ............................................................................................................................................................. 550,100 550,100

Codeine (for sale) ............................................................................................................................................. 62,020,000 62,020,000

Codeine (for conversion) .................................................................................................................................. 18,460,000 23,906,000

Desoxyephedrine 1,151,000 grams of levodesoxyephedrine for use in a non-controlled, non-prescription

product and 32,000 grams for methamphetamine ........................................................................................ 1,332,000 1,183,000

Dextropropoxyphene ......................................................................................................................................... 109,500,000 109,500,000

Dihydrocodeine ................................................................................................................................................. 189,000 46,000

Diphenoxylate ................................................................................................................................................... 1,600,000 1,600,000

Ecgonine ........................................................................................................................................................... 651,000 651,000

Ethylmorphine ................................................................................................................................................... 12 12

Fentanyl ............................................................................................................................................................ 202,000 202,000

Glutethimide ...................................................................................................................................................... 2 2

Hydrocodone (for sale) ..................................................................................................................................... 13,908,000 16,314,000

Hydrocodone (for conversion) .......................................................................................................................... 3,000,000 3,000,000

Hydromorphone ................................................................................................................................................ 766,000 766,000

Isomethadone ................................................................................................................................................... 12 12

Levo-alpha-acetylmethadol (LAAM) .................................................................................................................. 356,000 356,000

Levomethorphan ............................................................................................................................................... 2 2

Levorphanol ...................................................................................................................................................... 15,000 15,000

Meperidine ........................................................................................................................................................ 9,311,000 9,745,000

Methadone (for sale) ......................................................................................................................................... 3,790,000 5,413,000

Methadone (for conversion) .............................................................................................................................. 1,169,000 585,000

Methadone Intermediate ................................................................................................................................... 6,777,000 7,488,000

Methamphetamine (for conversion) .................................................................................................................. 723,000 723,000

Methylphenidate ................................................................................................................................................ 14,442,000 14,442,000

Morphine (for sale) ............................................................................................................................................ 11,535,000 12,034,000

Morphine (for conversion) ................................................................................................................................. 75,918,000 75,918,000

Nabilone ............................................................................................................................................................ 2 2

Noroxymorphone (for sale) ............................................................................................................................... 25,000 25,000

Noroxymorphone (for conversion) .................................................................................................................... 2,117,000 2,177,000

Opium ................................................................................................................................................................ 615,000 615,000

Oxycodone (for sale) ........................................................................................................................................ 9,032,000 9,451,000

Oxymorphone .................................................................................................................................................... 120,000 126,000

Pentobarbital ..................................................................................................................................................... 16,562,000 16,562,000

Phencyclidine .................................................................................................................................................... 60 60

Phenmetrazine .................................................................................................................................................. 2 2

Phenylacetone .................................................................................................................................................. 10 10

Secobarbital ...................................................................................................................................................... 301,000 397,000

Sufentanil .......................................................................................................................................................... 700 1,800

Thebaine ........................................................................................................................................................... 9,580,000 13,230,000

The Acting Deputy Administrator

further proposes that aggregate

production quotas for all other

Schedules I and II controlled substances

including §§ 1308.11 and 1308.12 of

Title 21 of the Code of Federal

Regulations remain at zero.

All interested persons are invited to

submit their comments and objections

in writing regarding this proposal. A

person may object to or comment on the

proposal relating to any of the abovementioned substances without filing

comments or objections regarding the

others. If a person believes that one or

more of these issues warrant a hearing,

the individual should so state and

summarize the reasons for this belief.

In the event that comments or

objections to this proposal raise one or

more issues which the Acting Deputy

Administrator finds warrant a hearing,

the Acting Deputy Administrator shall

order a public hearing by notice in the

Federal Register, summarizing the

issues to be heard and setting the time

for the hearing.

The Office of Management and Budget

has determined that notices of aggregate

production quotas are not subject to

centralized review under Executive

Order 12866. This action has been

analyzed in accordance with the

principles and criteria contained in

Executive Order 12612, and it has been

determined that this matter does not

have sufficient federalism implications

to warrant the preparation of a

Federalism Assessment.

The Acting Deputy Administrator

hereby certifies that this action will

have no significant impact upon small

entities whose interests must be

considered under the Regulatory

Flexibility Act, 5 U.S.C. 601 et seq. The

establishment of aggregate production

quotas for Schedule I and II controlled

substances is mandated by law and by

international treaty obligations.

Aggregate production quotas apply to
38674 Federal Register / Vol. 63, No. 137 / Friday, July 17, 1998 / Notices

approximately 200 DEA registered bulk

and dosage from manufacturers of

Schedules I and II controlled

substances. The quotas are necessary to

provide for the estimated medical,

scientific, research and industrial needs

of the United States, for export

requirements and the establishment and

maintenance of reserve stocks. While

aggregate production quotas are of

primary importance to large

manufacturers, their impact upon small

entities is neither negative nor

beneficial. Accordingly, the Acting

Deputy Administrator has determined

that this action does not require a

regulatory flexibility analysis.

Donnie R. Marshall,

Acting Deputy Administrator.

[FR Doc. 98–19084 Filed 7–16–98; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Office of the Solicitor

Agency Information Collection

Activities: Proposed Collection;

Comment Request; Equal Access to

Justice Act

ACTION: Notice.

SUMMARY: The Department of Labor, as

part of its continuing effort to reduce

paperwork and respondent burden,

conducts a preclearance consultation

program to provide the general public

and Federal agencies with an

opportunity to comment on proposed

and/or continuing collections of

information in accordance with the

Paperwork Reduction Act of 1995

(PRA95) [44 U.S.C. 3505(c)(2)(A)]. The

program helps to ensure that requested

data can be provided in the desired

format, reporting burden (time and

financial resources) is minimized,

collection instruments are clearly

understood, and the impact of the

collection requirements on respondents

can be properly assessed. Currently the

Office of the Solicitor is soliciting

comment concerning the proposed

extension of the information collection

request (ICR) for applications to obtain

awards in administrative proceedings

subject to the Equal Access to Justice

Act.

The Department of Labor is

particularly interested in comments

which:

• Evaluate whether the proposed

collection of information is necessary

for the proper performance of the

functions of the agency, including

whether the information will have

practical utility;

• Evaluate the accuracy of the

agency’s estimate of the burden of the

proposed collection of information,

including the validity of the

methodology and assumptions used;

• Enhance the quality, utility, and

clarity of the information to be

collected; and

• Minimize the burden of the

collection of information on those who

are to respond, including through the

use of appropriate automated,

electronic, mechanical, or other

technological collection techniques or

other forms of information technology,

e.g., permitting electronic submission of

responses.

DATES: Written comments must be

submitted by September 15, 1998.

ADDRESSES: Comments are to be

submitted to Department of Labor/The

Office of Solicitor Attn: Peter Galvin,

200 Constitution Avenue, N.W. (Room

N–2428) Washington D.C. 20210).

Written comments limited to 10 pages

or fewer may be transmitted by

facsimile to (202) 219–6896.

FOR FURTHER INFORMATION CONTACT:

Contact Peter Galvin, The Office of

Solicitor, telephone (202) 219–8065 or

Todd Owen at (202) 219–5096 (ext 143).

Copies of the referenced information

collection request are available in room

N–1301, U.S. Department of Labor, 200

Constitution Avenue N.W., Washington,

D.C. 20210. A copy of the ICR, with

applicable supporting documentation,

may be obtained by calling the

Department of Labor, Departmental

Clearance Officer, Todd R. Owen ({202}

219–5096 Ext. 143) or by E-Mail to

Owen-Todd@dol. gov.

SUPPLEMENTARY INFORMATION:

I. Background

The Equal Access to Justice Act

provides for the award of fees and

expenses to certain parties involved in

administrative proceedings with the

United States. The statute requires, at 5

U.S.C. sec. 504(a)(2), that a party

seeking an award of fees and other

expenses in a covered administrative

proceeding must submit to the agency

‘‘an application which shows that the

party is prevailing party and is eligible

to receive an award’’ under the Act. The

Department of Labor’s regulations

implementing the Equal Access to

Justice Act contain a subpart which

specifies the contents of applications for

an award, 29 CFR Part 16, Subpart B.

II. Current Actions

This notice requests an extension of

the current Office of Management and

Budget (OMB) approval of the

paperwork requirements for the

contents of applications for an award

under the Equal Access to Justice Act.

Type of Review: Extension.

Agency: Office of the Solicitor.

Title: Equal Access to Justice Act.

OMB Number: 1225–0013.

Affected Public: Individuals or

household; Business or other for-profit;

Not-for-profit institutions; Federal

Government; State, Local or Tribal

Government.

Total Respondents: 10.

Frequency: On occasion.

Total Responses: 10.

Average Time per Response: 5 hours.

Estimated Total Burden Hours. 1

hour.

Total Annualized capital/startup

costs: 0.

Total initial costs: 0.

Comments submitted in response to

this notice will be summarized and may

be included in the request for OMB

approval of the final information

collection request. The comments will

become a matter of public record.

Dated: July 13, 1998.

Robert A. Shapiro,

Associate Solicitor for Legislation and Legal

Counsel.

[FR Doc. 98–19111 Filed 7–16–98; 8:45 am]

BILLING CODE 4510–23–M

DEPARTMENT OF LABOR

Employment Standards

Administration, Wage and Hour

Division

Minimum Wages for Federal and

Federally Assisted Construction;

General Wage Determination Decisions

General wage determination decisions

of the Secretary of Labor are issued in

accordance with applicable law and are

based on the information obtained by

the Department of Labor from its study

of local wage conditions and data made

available from other sources. They

specify the basic hourly wage rates and

fringe benefits which are determined to

be prevailing for the described classes of

laborers and mechanics employed on

construction projects of a similar

character and in the localities specified

therein.

The determinations in these decisions

of prevailing rates and fringe benefits

have been made in accordance with 29

CFR Part 1, by authority of the Secretary

of Labor pursuant to the provisions of

the Davis-Bacon Act of March 3, 1931,

as amended (46 Stat. 1494, as amended,

40 U.S.C. 276a) and of other Federal

statutes referred to in 29 CFR Part 1,

Appendix, as well as such additional

statutes as may from time to time be